INVITATIONS TO INDUSTRY (I2I)

MEET OUR SEMINAR SPEAKER

ELEFTHERIA PISSADAKI, PhD
Manager, Systems Neuroscientist, Biogen Digital Health at Biogen

University of Crete
Ph.D., Computational Neuroscience, Neurobiology
University of Crete
M.S., Neuroscience, Neurobiology

Zoom link will be sent to graduate students and postdocs in participating departments

WHEN: Thursday, Mar 31 | 12 PM ET
WHERE: Zoom Video Conferencing

To learn more about Dr. Pissadaki or Biogen, please see the links below.

Eleftheria Pissadaki, PhD: https://www.linkedin.com/in/eleftheria-k-pissadaki-phd-26240819/
Dr. Pissadaki is a deep insight visionary interdisciplinary neuroscientist and a multirole research manager, leading research and innovation activities in the fields of neuroscience, complex data analysis, digital medicine and blockchain technology. She has experience gained through appointments in world class universities, IT and pharmaceutical companies fused into skills and profile structured for pushing science and innovation challenges beyond limits and expectations. Her primal vision is to develop and research ideas, turn them into projects and deliverables, and build organizations for impacting and alleviating suffering in health conditions. Finding out the right space and mission for leading with full dedication on inherently complex problems, while succeeding even when background is limited, or results are deserted. Dr. Pissadaki is an alumna of the University of Crete where she earned her PhD in Computational Neuroscience, Neurobiology and her MS in Neuroscience, Neurobiology, and Neurosciences. She completed her post-doctoral fellowship at the University of Oxford in Neuroscience.

Biogen: https://www.biogen.com/
"Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube."